MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meetin...
October 13 2020 - 6:30AM
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ
Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo
Stock Exchange (Code Number: 4875), today announced positive
findings from a study evaluating MN-001 (tipelukast) in an acute
liver injury model will be presented at The Liver Meeting Digital
Experience™ 2020 (TLMdX™), an event of the American Association for
the Study of Liver Diseases (AASLD). The study is the results of a
collaborative effort between MediciNova and Dr. Craig McClain and
Dr. Leila Gobejishvili at the University of Lousiville School of
Medicine.
The poster presentation entitled "MODULATION OF TGFβ1 SIGNALING
BY INTERACTION OF cAMP EFFECTORS AND TGFβ1 TYPE I RECEPTOR IN
HEPATIC STELLATE CELLS" is authored by principal researcher, Dr.
Leila Gobejishvili, Associate Professor, University of Louisville
School of Medicine, Division of Gastroenterology, Hepatology and
Nutrition.
Due to the COVID-19 pandemic, TLMdX™ will be held November
13-16, 2020 in its digital format. The poster session will be open
and available during the entirety of TLMdX™ 2020.
Presentation details are as follows:
Publication Number: 0317
Session Title: Basic Fibrosis Research and
Stellate Cell Biology
Presentation Type: Poster Presentation
Dates:
November 13-16, 2020
About MN-001
MN-001 (tipelukast) is a novel, orally bioavailable, small
molecule compound thought to exert its effects through several
mechanisms to produce its anti-inflammatory and anti-fibrotic
activity in preclinical models, including leukotriene (LT) receptor
antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and
4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway
has been postulated as a pathogenic factor in fibrosis development,
and MN-001's inhibitory effect on 5-LO and the 5-LO/LT pathway is
considered to be a novel approach to treat fibrosis. MN-001 has
been shown to down-regulate expression of genes that promote
fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has
also been shown to down-regulate expression of genes that promote
inflammation including CCR2 and MCP-1. In addition,
histopathological data shows that MN-001 reduces fibrosis in
multiple animal models.
About MediciNova
MediciNova, Inc. is a publicly traded
biopharmaceutical company founded upon developing novel,
small-molecule therapeutics for the treatment of diseases with
unmet medical needs with a primary commercial focus on the U.S.
market. MediciNova's current strategy is to focus on BC-PIV
SARS-COV-2 vaccine for COVID-19, MN-166 (ibudilast) for
neurological disorders such as progressive multiple sclerosis (MS),
amyotrophic lateral sclerosis (ALS), degenerative cervical
myelopathy (DCM), substance dependence (e.g., alcohol use disorder,
methamphetamine dependence, opioid dependence) and glioblastoma
(GBM), as well as prevention of acute respiratory distress syndrome
(ARDS) caused by COVID-19, and MN-001 (tipelukast) for fibrotic
diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic
pulmonary fibrosis (IPF). MediciNova’s pipeline also includes
MN-221 (bedoradrine) and MN-029 (denibulin). For more information
on MediciNova, Inc., please visit www.medicinova.com.
Statements in this press release that are not
historical in nature constitute forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements
include, without limitation, statements regarding the future
development and efficacy of BC-PIV SARS-COV-2 vaccine, MN-166,
MN-001, MN-221, and MN-029. These forward-looking statements may be
preceded by, followed by or otherwise include the words "believes,"
"expects," "anticipates," "intends," "estimates," "projects,"
"can," "could," "may," "will," "would," “considering,” “planning”
or similar expressions. These forward-looking statements involve a
number of risks and uncertainties that may cause actual results or
events to differ materially from those expressed or implied by such
forward-looking statements. Factors that may cause actual results
or events to differ materially from those expressed or implied by
these forward-looking statements include, but are not limited to,
risks of obtaining future partner or grant funding for development
of BC-PIV SARS-COV-2 vaccine, MN-166, MN-001, MN-221, and MN-029
and risks of raising sufficient capital when needed to fund
MediciNova's operations and contribution to clinical development,
risks and uncertainties inherent in clinical trials, including the
potential cost, expected timing and risks associated with clinical
trials designed to meet FDA guidance and the viability of further
development considering these factors, product development and
commercialization risks, the uncertainty of whether the results of
clinical trials will be predictive of results in later stages of
product development, the risk of delays or failure to obtain or
maintain regulatory approval, risks associated with the reliance on
third parties to sponsor and fund clinical trials, risks regarding
intellectual property rights in product candidates and the ability
to defend and enforce such intellectual property rights, the risk
of failure of the third parties upon whom MediciNova relies to
conduct its clinical trials and manufacture its product candidates
to perform as expected, the risk of increased cost and delays due
to delays in the commencement, enrollment, completion or analysis
of clinical trials or significant issues regarding the adequacy of
clinical trial designs or the execution of clinical trials, and the
timing of expected filings with the regulatory authorities,
MediciNova's collaborations with third parties, the availability of
funds to complete product development plans and MediciNova's
ability to obtain third party funding for programs and raise
sufficient capital when needed, and the other risks and
uncertainties described in MediciNova's filings with the Securities
and Exchange Commission, including its annual report on Form 10-K
for the year ended December 31, 2019 and its subsequent periodic
reports on Form 10-Q and current reports on Form 8-K. Undue
reliance should not be placed on these forward-looking statements,
which speak only as of the date hereof. MediciNova disclaims any
intent or obligation to revise or update these forward-looking
statements.
INVESTOR CONTACT:Geoff O'BrienVice PresidentMediciNova,
Inc.info@medicinova.com
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Apr 2023 to Apr 2024